What Companies Are In The VanEck Semiconductor ETF?
There’s a lot to love about the VanEck Semiconductor ETF,…
Sell
41
PSTV Quote, Financials, Valuation and Earnings
Last price:
$1.22
Seasonality move
:
6.33%
Day range:
$1.18 - $1.24
52-week range:
$0.93 - $2.67
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
1.35x
P/B ratio:
--
Volume:
43.9K
Avg. volume:
70.5K
1-year change:
-32.04%
Market cap:
$7.3M
Revenue:
--
EPS (TTM):
-$2.53
Analysts' Opinion
-
Consensus RatingPlus Therapeutics has received a consensus rating of Buy. The company's average rating is a Buy based on 2 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $15.75, Plus Therapeutics has an estimated upside of 1180.49% from its current price of $1.23.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $4.00 representing 100% downside risk from its current price of $1.23.
Fair Value
-
According to the consensus of 2 analysts, Plus Therapeutics has 1180.49% upside to fair value with a price target of $15.75 per share.
PSTV vs. S&P 500
-
Over the past 5 trading days, Plus Therapeutics has overperformed the S&P 500 by 14.43% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Plus Therapeutics does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Plus Therapeutics revenues have been falling on a year-over-year basis for 3 quarters in a row. In the most recent quarter Plus Therapeutics reported revenues of --.
Earnings Growth
-
Plus Therapeutics has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Plus Therapeutics reported earnings per share of -$0.37.
Enterprise value:
5.8M
EV / Invested capital:
--
Price / LTM sales:
1.35x
EV / EBIT:
--
EV / Revenue:
0.92x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-0.48x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
--
Net Income Margin (TTM):
--
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$18M | -$15M | -$14.7M | -$3.3M | -$3.8M | |
| EBITDA | -$17.3M | -$14M | -$8.5M | -$2.9M | -$2.6M | |
| Diluted EPS | -$13.31 | -$6.02 | -$2.53 | -$1.00 | -$0.37 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $8.6M | $22.1M | $20.9M | $11.6M | $5.4M | |
| Total Assets | $11.7M | $24.8M | $23.1M | $13.3M | $7M | |
| Current Liabilities | $8.4M | $9.5M | $7.4M | $10.5M | $12.1M | |
| Total Liabilities | $9M | $10M | $11.7M | $10.7M | $12.2M | |
| Total Equity | $2.6M | $14.8M | $11.4M | $2.6M | -$5.2M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$13.4M | -$13.2M | -$11.2M | -$2.4M | -$3.7M | |
| Cash From Investing | -$746K | -$129K | -$4.2M | -$10K | -$9K | |
| Cash From Financing | $13.1M | $4.1M | $5.7M | $2.5M | -- | |
| Free Cash Flow | -$14.1M | -$13.3M | -$11.9M | -$2.4M | -$3.7M | |
PSTV
Sector
Market Cap
$7.3M
$49.2M
Price % of 52-Week High
46.06%
48.57%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.74%
1-Year Price Total Return
-32.04%
-30.94%
Beta (5-Year)
0.696
0.754
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Buy
Level
$1.14
200-day SMA
Sell
Level
$1.61
Bollinger Bands (100)
Sell
Level
1.2 - 1.5
Chaikin Money Flow
Sell
Level
-553.7M
20-day SMA
Buy
Level
$1.19
Relative Strength Index (RSI14)
Buy
Level
53.63
ADX Line
Buy
Level
16.96
Williams %R
Neutral
Level
-24.0349
50-day SMA
Sell
Level
$1.25
MACD (12, 26)
Sell
Level
-0.03
25-day Aroon Oscillator
Sell
Level
-36
On Balance Volume
Neutral
Level
512.3M
Financial Scores
--
Altman Z-Score
(Annual)
Level (--)
--
CA Score
(Annual)
Level (--)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (3)
--
Ohlson Score
Level (--)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Plus Therapeutics Inc is a clinical-stage pharmaceutical company that focuses on discovering, developing, and delivering complex treatments for patients with cancer and rare diseases. The company is working on a range of potential products, with its main programs targeting recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). One of its key candidates, rhenium (186Re) obisbemeda, is specifically designed to treat central nervous system (CNS) cancers such as GBM, LM, and pediatric brain cancers (PBC).
Stock Forecast FAQ
In the current month, PSTV has received 2 Buy ratings 0 Hold ratings, and 0 Sell ratings. The PSTV average analyst price target in the past 3 months is $15.75.
-
Where Will Plus Therapeutics Stock Be In 1 Year?
According to analysts, the consensus estimate is that Plus Therapeutics share price will rise to $15.75 per share over the next 12 months.
-
What Do Analysts Say About Plus Therapeutics?
Analysts are divided on their view about Plus Therapeutics share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Plus Therapeutics is a Sell and believe this share price will drop from its current level to $4.00.
-
What Is Plus Therapeutics's Price Target?
The price target for Plus Therapeutics over the next 1-year time period is forecast to be $15.75 according to 2 Wall Street analysts, 2 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is PSTV A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Plus Therapeutics is a Buy. 2 of 2 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of PSTV?
You can purchase shares of Plus Therapeutics via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Plus Therapeutics shares.
-
What Is The Plus Therapeutics Share Price Today?
Plus Therapeutics was last trading at $1.22 per share. This represents the most recent stock quote for Plus Therapeutics. Yesterday, Plus Therapeutics closed at $1.23 per share.
-
How To Buy Plus Therapeutics Stock Online?
In order to purchase Plus Therapeutics stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
How High Can Palantir Stock Go?
Palantir Technologies (NASDAQ:PLTR) has been one of the undisputed victors…
Will This ETF Beat the Market Over the Next 12 Months?
2024 was another banner year for the US stock market,…
Stock Ideas
Sell
48
Is AAPL Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 40x
Buy
56
Is NVDA Stock a Buy?
Market Cap: $3.5T
P/E Ratio: 121x
Sell
46
Is MSFT Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 36x
Alerts
Sell
39
DOGZ alert for Jan 4
Dogness (International) [DOGZ] is down 20.52% over the past day.
Buy
66
DMRC alert for Jan 4
Digimarc [DMRC] is up 16.19% over the past day.
Sell
39
MSTR alert for Jan 4
MicroStrategy [MSTR] is up 13.33% over the past day.
